Vitaliy Kuznets

Vitaliy Kuznets

Auto-generated profile, based on publicly available information

Vitaliy Kuznets

I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
PDF file
ASAlexandr Serhiyenko
Alexandr Serhiyenko
MBMyroslav Baitsar
Myroslav Baitsar
VSVolodymyr Sehin
Volodymyr Sehin
LSLudmila Serhiyenko
Ludmila Serhiyenko
VKVitaliy Kuznets
Vitaliy Kuznets
ASAlexandr Serhiyenko
Alexandr Serhiyenko
This narrative review was aimed to analyze the scientific data about the association of post-traumatic stress disorder, insomnia, obstructive sleep apnea syndrome, dyssomnias, heart rate variability, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular autonomic neuropathy, along with potential pathophysiological mechanisms underlying these associations. The results of experimental, cohort, prospective, and randomized clinical studies provide evidence of common pathogenetic pathways contributing to their development. Searches were conducted in Scopus, Science Direct (from Elsevier), EBSCO, and PubMed databases, including the Medline databases. Additionally, a manual search of publication bibliographies was undertaken to uncover research outcomes not accessible through online searches.

30 May 2024 in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Verified
Journal Article
Open access
PDF file
ОSО.о. Serhiyenko
О.о. Serhiyenko
VSV.B. Sehin
V.B. Sehin
VKV.о. Kuznets
V.о. Kuznets
ASAlexandr Serhiyenko
Alexandr Serhiyenko
Melatonin has several impacts on the cardiovascular system, including the potential to reduce blood pressure in addition to its role in regulating sleep. It has the ability to decrease adrenergic system activity and indirectly enhance endothelial function. Melatonin can provide antihypertensive effects by stimu­lating own receptors in the central nervous system and peripheral arteries. In addition, melatonin is a potential treatment for patients with hypertension, including the “night-peaker” category. Howe­ver, the results of only a few randomized trials suggest that melatonin supplements are effective in the treatment of hypertension. Melatonin can lower blood pressure due to vasodilatation, direct blocking of Ca2+ channels and increased production of nitric oxide in the endothelium; antioxidant properties; suppression of the sympathetic nervous system, reduction of norepinephrine production, as well as activation of the parasympathetic nervous system. Because the drug is usually taken at bedtime, it may increase the duration and quality of sleep and therefore lower blood pressure during sleep. Low endogenous melatonin secretion during sleep may be associated with elevated nocturnal blood pressure and comorbid cardiovascular diseases. In addition, melatonin exhibits an excellent safety profile. Consequently, larger-scale, longer-term studies with higher patient heterogeneity, biomarker identification, and idiosyncrasies related to melatonin use are required. The aim of this narrative review is to analyze the peculiarities of the mecha­nisms of action, as well as the effect of exogenous melatonin on blood pressure parameters in the experiment and clinic. The search was conducted in Scopus, Science Direct (from Elsevier), and PubMed, including the MEDLINE databases. The key words used were “melatonin,” “blood pressure”, “hypertension”, “obesity”, “metabolic syndrome”. We manually searched the bibliography of publications to find study results that the online search did not yield.